Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908928 · ClinicalTrials.gov registry record · Phase 1
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
A Phase 1 study of Triple Negative Breast Cancer, sponsored by Mabwell (Shanghai) Bioscience Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 6
- Study locations
NCT06908928: Recruiting Phase 1 study of Triple Negative Breast Cancer, sponsored by Mabwell (Shanghai) Bioscience Co..
NCT06908928 is a Phase 1 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Mabwell (Shanghai) Bioscience Co.. The registered enrollment target is 52 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (79% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06908928, a Phase 1 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Mabwell (Shanghai) Bioscience Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Primary Outcome
Objective Response Rate according to RECIST v1.1 by investigator assessment
Conditions Studied
Interventions
- DRUG bulumtatug fuvedotin
Study Locations (6)
California
- City of Hope - Duarte
- UCSD Moores Cancer Center - La Jolla
Colorado
- Anschutz Medical Center - Aurora
Illinois
- UChicago Medicine Comprehensive Cancer Center - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
What NCT06908928 shows while recruiting
NCT06908928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which bulumtatug fuvedotin is the first listed.
NCT06908928 lists 6 locations in 5 states (California, Colorado, Illinois).
Frequently Asked Questions
What is clinical trial NCT06908928 about?
NCT06908928 is a clinical study titled "A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs". The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
What is the current status of trial NCT06908928?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-08-11. Estimated completion is 2028-05.
What conditions does trial NCT06908928 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT06908928?
The interventions under investigation include: bulumtatug fuvedotin (DRUG).
Who is sponsoring clinical trial NCT06908928?
This trial is sponsored by Mabwell (Shanghai) Bioscience Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908928 being conducted?
This trial has 6 study locations across California, Colorado, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06908928's enrollment target sits among peer trials
52 72nd of 118 higher than 47 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI